Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance

Roberto Fogari, Giuseppe Derosa, Pierangelo Lazzari, Annalisa Zoppi, Elena Fogari, Andrea Rinaldi, Amedeo Mugellini

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

The aim of this study was to evaluate the effect of the amlodipine-atorvastatin combination on plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) activity in hypercholesterolemic, hypertensive patients with insulin resistance. The study population included 45 patients, aged 41 to 70 years, with mild to moderate essential hypertension (diastolic blood pressure [BP] ≥95 and ≤105 mm Hg), hypercholesterolemia (total cholesterol >200 and 2.5) After a 4-week wash-out period, they were randomized to amlodipine (5 mg) or atorvastatin (20 mg) or their combination at the same oral dosage for 12 weeks in three cross-over periods each separated by a 4-week placebo period (3 by 3 latin square design). At the end of the placebo wash-out and of each treatment period, office BP, total cholesterol, PAI-1, and t-PA activity were evaluated. The amlodipine-atorvastatin combination, in addition to the expected hypocholesterolemic effect, produced: 1) a greater decrease in PAI-1 activity (-10.2 U/mL, P <.01 v placebo) and an even greater increase in t-PA activity (+0.26 U/mL, P <.01 v placebo) than amlodipine (-0.5 U/mL for PAI-1, P = not significant; +0.17 U/mL for t-PA, P <.01 v placebo) and atorvastatin alone (respectively, -9.9 U/mL, P <.01 v placebo and +0.08 U/mL, P <.05 v placebo); and 2) a greater systolic BP/diastolic BP mean reduction (-22/17 mm Hg, P <.005 v placebo) than amlodipine (-18/14 mm Hg, P <.01 v placebo) and atorvastatin alone (-2.8/3.8 mm Hg, P <.05 v placebo only for diastolic BP). The positive effect on fibrinolytic balance and BP control observed suggests that in hypertensive, hypercholesterolemic patients with impaired fibrinolysis, the combination of amlodipine and atorvastatin could be the treatment of choice.

Original languageEnglish
Pages (from-to)823-827
Number of pages5
JournalAmerican Journal of Hypertension
Volume17
Issue number9
DOIs
Publication statusPublished - Sep 2004

Fingerprint

Fibrinolysis
Insulin Resistance
Placebos
Blood Pressure
Tissue Plasminogen Activator
Amlodipine
Plasminogen Activator Inhibitor 1
Cholesterol
atorvastatin drug combination amlodipine
Plasminogen Inactivators
Urokinase-Type Plasminogen Activator
Hypercholesterolemia

Keywords

  • Amlodipine
  • atorvastatin
  • fibrinolysis
  • hypercholesterolemia
  • hypertension

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. / Fogari, Roberto; Derosa, Giuseppe; Lazzari, Pierangelo; Zoppi, Annalisa; Fogari, Elena; Rinaldi, Andrea; Mugellini, Amedeo.

In: American Journal of Hypertension, Vol. 17, No. 9, 09.2004, p. 823-827.

Research output: Contribution to journalArticle

Fogari, Roberto ; Derosa, Giuseppe ; Lazzari, Pierangelo ; Zoppi, Annalisa ; Fogari, Elena ; Rinaldi, Andrea ; Mugellini, Amedeo. / Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. In: American Journal of Hypertension. 2004 ; Vol. 17, No. 9. pp. 823-827.
@article{cd0f39faa2c14e1dad1ac2d4ae2c13cf,
title = "Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance",
abstract = "The aim of this study was to evaluate the effect of the amlodipine-atorvastatin combination on plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) activity in hypercholesterolemic, hypertensive patients with insulin resistance. The study population included 45 patients, aged 41 to 70 years, with mild to moderate essential hypertension (diastolic blood pressure [BP] ≥95 and ≤105 mm Hg), hypercholesterolemia (total cholesterol >200 and 2.5) After a 4-week wash-out period, they were randomized to amlodipine (5 mg) or atorvastatin (20 mg) or their combination at the same oral dosage for 12 weeks in three cross-over periods each separated by a 4-week placebo period (3 by 3 latin square design). At the end of the placebo wash-out and of each treatment period, office BP, total cholesterol, PAI-1, and t-PA activity were evaluated. The amlodipine-atorvastatin combination, in addition to the expected hypocholesterolemic effect, produced: 1) a greater decrease in PAI-1 activity (-10.2 U/mL, P <.01 v placebo) and an even greater increase in t-PA activity (+0.26 U/mL, P <.01 v placebo) than amlodipine (-0.5 U/mL for PAI-1, P = not significant; +0.17 U/mL for t-PA, P <.01 v placebo) and atorvastatin alone (respectively, -9.9 U/mL, P <.01 v placebo and +0.08 U/mL, P <.05 v placebo); and 2) a greater systolic BP/diastolic BP mean reduction (-22/17 mm Hg, P <.005 v placebo) than amlodipine (-18/14 mm Hg, P <.01 v placebo) and atorvastatin alone (-2.8/3.8 mm Hg, P <.05 v placebo only for diastolic BP). The positive effect on fibrinolytic balance and BP control observed suggests that in hypertensive, hypercholesterolemic patients with impaired fibrinolysis, the combination of amlodipine and atorvastatin could be the treatment of choice.",
keywords = "Amlodipine, atorvastatin, fibrinolysis, hypercholesterolemia, hypertension",
author = "Roberto Fogari and Giuseppe Derosa and Pierangelo Lazzari and Annalisa Zoppi and Elena Fogari and Andrea Rinaldi and Amedeo Mugellini",
year = "2004",
month = "9",
doi = "10.1016/j.amjhyper.2004.06.005",
language = "English",
volume = "17",
pages = "823--827",
journal = "American Journal of Hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance

AU - Fogari, Roberto

AU - Derosa, Giuseppe

AU - Lazzari, Pierangelo

AU - Zoppi, Annalisa

AU - Fogari, Elena

AU - Rinaldi, Andrea

AU - Mugellini, Amedeo

PY - 2004/9

Y1 - 2004/9

N2 - The aim of this study was to evaluate the effect of the amlodipine-atorvastatin combination on plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) activity in hypercholesterolemic, hypertensive patients with insulin resistance. The study population included 45 patients, aged 41 to 70 years, with mild to moderate essential hypertension (diastolic blood pressure [BP] ≥95 and ≤105 mm Hg), hypercholesterolemia (total cholesterol >200 and 2.5) After a 4-week wash-out period, they were randomized to amlodipine (5 mg) or atorvastatin (20 mg) or their combination at the same oral dosage for 12 weeks in three cross-over periods each separated by a 4-week placebo period (3 by 3 latin square design). At the end of the placebo wash-out and of each treatment period, office BP, total cholesterol, PAI-1, and t-PA activity were evaluated. The amlodipine-atorvastatin combination, in addition to the expected hypocholesterolemic effect, produced: 1) a greater decrease in PAI-1 activity (-10.2 U/mL, P <.01 v placebo) and an even greater increase in t-PA activity (+0.26 U/mL, P <.01 v placebo) than amlodipine (-0.5 U/mL for PAI-1, P = not significant; +0.17 U/mL for t-PA, P <.01 v placebo) and atorvastatin alone (respectively, -9.9 U/mL, P <.01 v placebo and +0.08 U/mL, P <.05 v placebo); and 2) a greater systolic BP/diastolic BP mean reduction (-22/17 mm Hg, P <.005 v placebo) than amlodipine (-18/14 mm Hg, P <.01 v placebo) and atorvastatin alone (-2.8/3.8 mm Hg, P <.05 v placebo only for diastolic BP). The positive effect on fibrinolytic balance and BP control observed suggests that in hypertensive, hypercholesterolemic patients with impaired fibrinolysis, the combination of amlodipine and atorvastatin could be the treatment of choice.

AB - The aim of this study was to evaluate the effect of the amlodipine-atorvastatin combination on plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) activity in hypercholesterolemic, hypertensive patients with insulin resistance. The study population included 45 patients, aged 41 to 70 years, with mild to moderate essential hypertension (diastolic blood pressure [BP] ≥95 and ≤105 mm Hg), hypercholesterolemia (total cholesterol >200 and 2.5) After a 4-week wash-out period, they were randomized to amlodipine (5 mg) or atorvastatin (20 mg) or their combination at the same oral dosage for 12 weeks in three cross-over periods each separated by a 4-week placebo period (3 by 3 latin square design). At the end of the placebo wash-out and of each treatment period, office BP, total cholesterol, PAI-1, and t-PA activity were evaluated. The amlodipine-atorvastatin combination, in addition to the expected hypocholesterolemic effect, produced: 1) a greater decrease in PAI-1 activity (-10.2 U/mL, P <.01 v placebo) and an even greater increase in t-PA activity (+0.26 U/mL, P <.01 v placebo) than amlodipine (-0.5 U/mL for PAI-1, P = not significant; +0.17 U/mL for t-PA, P <.01 v placebo) and atorvastatin alone (respectively, -9.9 U/mL, P <.01 v placebo and +0.08 U/mL, P <.05 v placebo); and 2) a greater systolic BP/diastolic BP mean reduction (-22/17 mm Hg, P <.005 v placebo) than amlodipine (-18/14 mm Hg, P <.01 v placebo) and atorvastatin alone (-2.8/3.8 mm Hg, P <.05 v placebo only for diastolic BP). The positive effect on fibrinolytic balance and BP control observed suggests that in hypertensive, hypercholesterolemic patients with impaired fibrinolysis, the combination of amlodipine and atorvastatin could be the treatment of choice.

KW - Amlodipine

KW - atorvastatin

KW - fibrinolysis

KW - hypercholesterolemia

KW - hypertension

UR - http://www.scopus.com/inward/record.url?scp=4444339708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444339708&partnerID=8YFLogxK

U2 - 10.1016/j.amjhyper.2004.06.005

DO - 10.1016/j.amjhyper.2004.06.005

M3 - Article

C2 - 15363826

AN - SCOPUS:4444339708

VL - 17

SP - 823

EP - 827

JO - American Journal of Hypertension

JF - American Journal of Hypertension

SN - 0895-7061

IS - 9

ER -